
















































Discussion Bryant and Cerfolio
1
G
TSome message from our study is that when integrated FDG-
ET/CT is used to clinically stage patients with NSCLC, the
linician should be aware that if the patient is smoking
igarettes at the time of the integrated FDG-PET/CT scan,
he maxSUV values might be lower, and the clinical accu-
acy might be lower as well.
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r David H. Harpole (Durham, NC). As usual, very nicely done
nd nicely presented. I would postulate that the difference in the
ymph nodes actually might be due to the histology of the lymph
odes, and it might be worth examining further because smokers
ave a lot of histiocytes that are just packed with material from the
moke. We have previously investigated this for a correlation with
he glut receptors. Therefore it is likely that these nodes are a little
ard to read from that standpoint and probably would have a lower
axSUV value just because there are more of these histiocytic
odes, which are full of anthracotic pigment and are not that
etabolically active, so that the tumors are a little more dispersed
n those nodes than in patients who were never smokers. The other
hing I would want to look at in those who never smoked is to see
ow many germinal centers there are in those nodes and how
acked the tumor is and so forth. I think these are excellent data.
am just trying to come up with sort of histopathologic reason why
here might be a difference in those nodes, but otherwise this is
ery nicely done.
Dr Bryant. Thank you, Dr Harpole. We agree with your
omments.
Dr Mark J. Krasna (Baltimore, Md). I am just wondering
bout the relationship between the smokers and those who never
moked versus sex. It seemed very apparent on that first slide that
ou were also looking at a group that had more women. With the
ew information on women, nonsmokers, and the prevalence of
ronchoalveolar carcinoma in that subset, can you perhaps give us
ome explanation on either how this might explain the findings or
ow you might go about trying to get rid of that possible bias in a
ollow-up study?
Dr Bryant. Thank you, Dr Krasna, for your question. There
s a propensity for bronchoalveolar carcinoma in the population
ho never smoked in this series. In our study we used a
ultivariate analysis model in which we controlled for sex, and
n doing so, we still found that the status of smoking, as well as
he maxSUV value, were independent predictors of accuracy on
ET scanning. Dose response was very close to being an
ndependent predictor, with a P value of .07, which is just
igher than the .05 level, the usual arbitrary cutoff to indicate
tatistical significance.
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